Key result
Truncated PCSK9 generated by in vivo cleavage lacks LDLR-binding ability and is biologically inactive.
Answers are grounded in this paper and cite their sources.
Proprotein convertase subtilisin-kexin type 9 (PCSK9) is a secreted protein which regulates serum LDL cholesterol. It circulates in human and rodent serum in an intact form and a major truncated form. Previous in vitro studies involving the expression of human PCSK9 genetic variants and in vivo studies of furin knockout mice suggest that the truncated form is a furin cleavage product. However, the circulating truncated form of PCSK9 has not been isolated and characterized. Utilizing antibodies which bind to either the catalytic domain or the C-terminal domain of PCSK9, the truncated PCSK9 was isolated from serum. MS was used to determine that this form of PCSK9 is a product of in vivo cleavage at Arg218 resulting in pyroglutamic acid formation of the nascent N terminus corresponding to Gln219 of intact PCSK9. We also determined that the truncated PCSK9 in serum lacked the N-terminal segment which contains amino acids critical for LDL receptor binding. A truncated PCSK9, expressed and purified from HEK293 cells with identical composition as the circulating truncated protein, was not active in inhibition of LDL uptake by HepG2 cells. These studies provide a definitive characterization of the composition and activity of the truncated form of PCSK9 found in human serum.
No takes yet. Share an insight, caveat, or question.
Han et al. (2014) studied LDL cholesterol regulation. Circulating truncated form of PCSK9 vs. Intact PCSK9 was evaluated on Composition and biological activity (inhibition of LDL uptake by HepG2 cells). Circulating truncated PCSK9 arises from in vivo cleavage at Arg218, lacks the N-terminal LDL receptor-binding segment, and is inactive in inhibiting LDL uptake by HepG2 cells.
Synapse has enriched 10 related papers. Consider them for comparative context: